Related Experiment Video
Updated: Apr 12, 2026
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
Published on: November 29, 2024
Silencing of miR-195 reduces diabetic cardiomyopathy in C57BL/6 mice
1Institutes of Biology and Medical Sciences, Soochow University, Suzhou, Jiangsu Province, China, 215123.
Aims/Hypothesis:
MicroRNAs (miRs) have been suggested as potential therapeutic targets for heart diseases. Inhibition of miR-195 prevents apoptosis in cardiomyocytes stimulated with palmitate and transgenic overexpression of miR-195 induces cardiac hypertrophy and heart failure. We investigated whether silencing of miR-195 reduces diabetic cardiomyopathy in a mouse model of streptozotocin (STZ)-induced type 1 diabetes.
Methods:
Type 1 diabetes was induced in C57BL/6 mice (male, 2 months old) by injections of STZ.
Results:
MiR-195 expression was increased and levels of its target proteins (B cell leukaemia/lymphoma 2 and sirtuin 1) were decreased in STZ-induced type 1 and db/db type 2 diabetic mouse hearts. Systemically delivering an anti-miR-195 construct knocked down miR-195 expression in the heart, reduced caspase-3 activity, decreased oxidative stress, attenuated myocardial hypertrophy and improved myocardial function in STZ-induced mice with a concurrent upregulation of B cell leukaemia/lymphoma 2 and sirtuin 1. Diabetes reduced myocardial capillary density and decreased maximal coronary blood flow in mice. Knockdown of miR-195 increased myocardial capillary density and improved maximal coronary blood flow in diabetic mice. Upregulation of miR-195 sufficiently induced apoptosis in cardiomyocytes and attenuated the angiogenesis of cardiac endothelial cells in vitro. Furthermore, inhibition of miR-195 prevented apoptosis in cardiac endothelial cells in response to NEFA, an important feature of diabetes.
Conclusions/Interpretation:
Therapeutic silencing of miR-195 reduces myocardial hypertrophy and improves coronary blood flow and myocardial function in diabetes, at least in part by reducing oxidative damage, inhibiting apoptosis and promoting angiogenesis. Thus, miR-195 may represent an alternative therapeutic target for diabetic heart diseases.
Insights
Silencing microRNA-195 (miR-195) in diabetic mice reduced heart problems like hypertrophy and poor blood flow. This suggests miR-195 is a potential therapeutic target for diabetic heart disease.
Area of Science:
- Cardiovascular Biology
- Molecular Medicine
- Diabetes Research
Background:
- MicroRNAs (miRs) are implicated in heart diseases.
- miR-195 dysregulation is linked to cardiac dysfunction, hypertrophy, and failure.
- Diabetic cardiomyopathy is a significant complication of diabetes mellitus.
Purpose of the Study:
- To investigate the therapeutic potential of silencing miR-195 in a mouse model of type 1 diabetes.
- To determine if inhibiting miR-195 can ameliorate diabetic cardiomyopathy.
Main Methods:
- Type 1 diabetes was induced in C57BL/6 mice using streptozotocin (STZ).
- Systemic delivery of an anti-miR-195 construct was used to silence miR-195.
- Cardiac function, oxidative stress, apoptosis, and angiogenesis were assessed.
Main Results:
- Increased miR-195 expression and decreased target proteins (Bcl2, Sirt1) were observed in diabetic hearts.
- miR-195 knockdown reduced apoptosis, oxidative stress, myocardial hypertrophy, and improved cardiac function.
- Silencing miR-195 increased myocardial capillary density and coronary blood flow in diabetic mice.
- In vitro studies showed miR-195 upregulation induced apoptosis and inhibited angiogenesis.
Conclusions:
- Therapeutic silencing of miR-195 effectively reduces myocardial hypertrophy and improves cardiac function in diabetes.
- miR-195 inhibition mitigates diabetic cardiomyopathy by reducing oxidative damage, inhibiting apoptosis, and promoting angiogenesis.
- miR-195 represents a promising therapeutic target for managing diabetic heart diseases.
